Literature DB >> 23908265

Designing the magic bullet? The advancement of immuno-PET into clinical use.

Brian D Wright1, Suzanne E Lapi.   

Abstract

The development of noninvasive imaging techniques using monoclonal antibodies (mAbs) is a quickly evolving field. Immuno-PET uses positron-emitting isotopes to track the localization of mAbs with excellent image quality. Procedures for labeling mAbs with (89)Zr or (124)I using good manufacturing procedures have been established, and therefore these radiopharmaceuticals are being investigated for clinical use. This short review will focus on immuno-PET with full mAbs using long-lived positron-emitting isotopes ((89)Zr and (124)I) over the past 5 y and discuss their progress into clinical use.

Keywords:  124I; 89Zr; PET; immuno-PET; positron

Mesh:

Substances:

Year:  2013        PMID: 23908265     DOI: 10.2967/jnumed.113.126086

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  26 in total

1.  Non-invasive nuclear imaging for localization of viral reservoirs.

Authors:  Ekaterina Dadachova; Joan W Berman
Journal:  Nat Methods       Date:  2015-05       Impact factor: 28.547

2.  Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development.

Authors:  Casey J Adams; Justin J Wilson; Eszter Boros
Journal:  Mol Pharm       Date:  2017-07-19       Impact factor: 4.939

3.  Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability.

Authors:  Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas
Journal:  Inorg Chem       Date:  2020-11-10       Impact factor: 5.165

4.  ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836.

Authors:  Reinier Hernandez; Christopher G England; Yunan Yang; Hector F Valdovinos; Bai Liu; Hing C Wong; Todd E Barnhart; Weibo Cai
Journal:  J Control Release       Date:  2017-08-24       Impact factor: 9.776

5.  Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.

Authors:  Sai Kiran Sharma; Andrew Chow; Sebastien Monette; Delphine Vivier; Jacob Pourat; Kimberly J Edwards; Thomas R Dilling; Dalya Abdel-Atti; Brian M Zeglis; John T Poirier; Jason S Lewis
Journal:  Cancer Res       Date:  2018-01-23       Impact factor: 12.701

Review 6.  Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.

Authors:  Emily B Ehlerding; Piotr Grodzinski; Weibo Cai; Christina H Liu
Journal:  ACS Nano       Date:  2018-03-01       Impact factor: 15.881

Review 7.  Update on time-of-flight PET imaging.

Authors:  Suleman Surti
Journal:  J Nucl Med       Date:  2014-12-18       Impact factor: 10.057

8.  Multimodal Positron Emission Tomography Imaging to Quantify Uptake of 89Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall.

Authors:  Mark E Lobatto; Tina Binderup; Philip M Robson; Luuk F P Giesen; Claudia Calcagno; Julia Witjes; Francois Fay; Samantha Baxter; Chang Ho Wessel; Mootaz Eldib; Jason Bini; Sean D Carlin; Erik S G Stroes; Gert Storm; Andreas Kjaer; Jason S Lewis; Thomas Reiner; Zahi A Fayad; Willem J M Mulder; Carlos Pérez-Medina
Journal:  Bioconjug Chem       Date:  2019-06-07       Impact factor: 4.774

9.  Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.

Authors:  Jae-Ho Lee; Heejung Kim; Zhengsheng Yao; Sung-Jin Lee; Lawrence P Szajek; Luigi Grasso; Ira Pastan; Chang H Paik
Journal:  Nucl Med Biol       Date:  2015-07-29       Impact factor: 2.408

10.  ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.

Authors:  Lei Kang; Dawei Jiang; Christopher G England; Todd E Barnhart; Bo Yu; Zachary T Rosenkrans; Rongfu Wang; Jonathan W Engle; Xiaojie Xu; Peng Huang; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-15       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.